Table I.
Previous case studies reporting on t(8;22)/breakpoint cluster region-fibroblast growth factor receptor 1 rearrangements.
| Author, year | Age (years), sex | Clinical manifestation prior to EMS diagnosis | Chromosomal abnormalities | Treatment | Outcome | (Refs.) |
|---|---|---|---|---|---|---|
| Fioretos, 2001 | 75, male | AML | 46,XY,t(8;22)(p11;q11) t(9;21)(q34;q22) | Not reported | Not reported | (3) |
| Demiroglou, 2001 | 65, female | CML-CP | Not reported | Hydroxyurea, IFNα | Alive on publication | (10) |
| Demiroglou, 2001 | 51, female | CML-CP | Not reported | Hydroxyurea, IFNα | Alive on publication | (10) |
| Pini, 2002 | 74, female | CML-CP | Not reported | Not reported | Not reported | (12) |
| Murati, 2005 | Not available | CML-CP and B-cell proliferation | Not available | Not available | Not reported | (13) |
| Agerstam, 2007 | 58, female | AML | 46,XY,t(8;22)(p11;q11) | Not reported | Not reported | (14) |
| Richebourg, 2008 | 56, female | CML, evolved to blast crisis | 47,XX,t(3;21)(q26;q22) t(8;22)(p11;q11), +der (22) | Hydroxyurea+IFNα, arsenic trioxide, cytarabine, daunorubicin+cytarabine | Death 24 months after presentation | (15) |
| Baldazzi, 2010 | 70, female | pre-ALL | 45,XX,del (3)(p11p21), del (7)(p12p15), t(8,22) (p11;q11), add (8)(p23), −9 | Induction combined chemotherapy | Death 24 months after presentation | (6) |
| Wakim, 2011 | 43, male | B-ALL | 45,XY,t6;11)(q11;p13), −7, t(8;22)(p11.2;q11.2), del (9) (p13p22) | Hyper-CVAD | Death | (5) |
| Haslam, 2012 | 21, male | B-ALL | 46,XY,t(8;22)(p12;q11)/45, idem, der (3;9)(q10;q10), dic (7;11)(p11;q13), +r (cp3) | FLAG, HSCT | Alive on publication | (9) |
| Morishige, 2012 | 50, male | Trilineage acute leukemia lymphoma | Not available | Cord blood | Alive on publication transplantation | (8) |
| Matikas, 2013 | 74, female | AML | 46,XX, del (5) q33q35, t(8;22)(p11;q11) | Mitoxantrone+etoposide, interferon, hydroxyurea, flutalazine | Alive on publication | (4) |
| Dolan, 2012 | 8, male | Juvenile myelomonocytic leukemia | 46,XY, inv (4)(p15.2q13), t(8;22)(p11;q11;q24) | Allogenic HSCT | Alive on publication | (7) |
| Qin, 2016 | 26, female | CML | 46,XX,t(8;22)(p11;q11) | Hydroxyurea | Alive on publication | (16) |
CML-CP, chronic myeloid leukemia in chronic phase; AML, acute myeloid leukemia; B-ALL, B-cell acute lymphoblastic leukemia; IFN, interferon; HSCT, hematopoietic stem cell transplantation; del, deletion; hyper-CVAD, hyperfractionated administration of cyclophosphamide, vincristine, doxorubicin and dexamethasone; idem, chromosomal abnormalities; der, translocation derived; dic, dimeric; FLAG, initial chemotherapy for acute monocytic leukemia; dic, dimeric centromeric; inv, inverted.